title: Initial success, frequent recurrence: tomorrow's multiple myeloma treatments and the value of subtype analysis. Interview with David Siegel.
authors.forename: David
authors.initials: D
authors.lastname: Siegel
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D008329:Managed Care Programs; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000517:prevention & control; D009842:Oligopeptides / Q000009:adverse effects / Q000627:therapeutic use; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D055502:Secondary Prevention; D017422:Sequence Analysis, DNA; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D009842:Oligopeptides; D013792:Thalidomide; C524865:carfilzomib; D000077269:Lenalidomide